Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: Current status

British Journal of Pharmacology

Volumn 160, Issue 6, 2010, Pages 1273-1292

  Ma, Terry K W ^a   Kam, Kevin K H ^a   Yan, Bryan P ^a   Lam, Yat Yin ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

angiotensin converting enzyme inhibitors; angiotensin II type 1 receptor blockers; diabetic nephropathy; heart failure; hypertension; myocardial infarction; renin angiotensin aldosterone system; stroke

Indexed keywords

ALDOSTERONE; ALISKIREN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; RENIN; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; ZOFENOPRIL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CARDIOVASCULAR AUTOREGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG RESEARCH; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; ANIMAL; CARDIOVASCULAR DISEASES; DRUG COMBINATION; DRUG EFFECTS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; PRACTICE GUIDELINES AS TOPIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 77954056940     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00750.x     Document Type: Review

References (159)

1. ACE Inhibitor Myocardial Infarction Collaborative Group (1998). Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 97 : 2202 2212.
2. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD (2006). Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 47 : 1576 1583.
3. Ambrosioni E, Borghi C, Magnani B (1995). The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) study investigators. N Engl J Med 332 : 80 85.
4. Bachmann S, Peters J, Engler E, Ganten D, Mullins J (1992). Transgenic rats carrying the mouse renin gene - morphological characterization of a low-renin hypertension model. Kidney Int 41 : 24 36.
5. Balcells E, Meng QC, Johnson WH Jr., Oparil S, Dell'Italia LJ (1997). Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 273 : H1769 H1774.
6. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J et al. (2004). Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351 : 1952 1961.
7. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN (1999). Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) study group. Circulation 99 : 2658 2664.
8. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D (2008). Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358 : 1887 1898.
9. Benedict CR, Johnstone DE, Weiner DH, Bourassa MG, Bittner V, Kay R et al 1994). Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD investigators. J Am Coll Cardiol 23 : 1410 1420.
10. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL et al 2005). Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 16 : 2170 2179.
11. Bertrand ME, Fox KM, Remme WJ, Ferrari R, Simoons ML (2009). Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial. Arch Cardiovasc Dis 102 : 89 96.
12. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B et al 2002). Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 324 : 699 702.
13. Braun-Menendez E, Page IH (1958). Suggested revision of nomenclature - angiotensin. Science 127 : 242.
14. Braun-Menendez E, Fasciolo JC, Leloir LF, Muñoz JM (1940). The substance causing renal hypertension. J Physiol 98 : 283 298.
15. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J et al 2004). PEACE Trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 : 2058 2068.
16. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al 2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861 869.
17. Brown JD, Plutzky J (2007). Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115 : 518 533.
18. Buch P, Rasmussen S, Abildstrom SZ, Køber L, Carlsen J, Torp-Pedersen C et al 2005). The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. Eur Heart J 26 : 145 152.
19. Bühler FR, Bolli P, Kiowski W, Erne P, Hulthén UL, Block LH (1984). Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med 77 : 36 42.
20. Bulpitt CJ, Beckett NS, Cooke J, Dumitrascu DL, Gil-Extremera B, Nachev C et al 2003). Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 21 : 2409 2417.
21. Campbell NR, Khan NA, Hill MD, Tremblay G, Lebel M, Kaczorowski J et al 2009). 2009 Canadian Hypertension Education Program recommendations: the scientific summary - an annual update. Can J Cardiol 25 : 271 277.
22. Carson P, Ziesche S, Johnson G, Cohn JN (1999). Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5 : 178 187.
23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al 2003). Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 : 1206 1252.
24. Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG (1997). Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study investigators. Eur Heart J 18 : 41 51.
25. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators (2001). A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 : 1667 1675.
26. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F et al 1991). A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 : 303 310.
27. Corvol P, Michaud A, Soubrier F, Williams TA (1995). Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme. J Hypertens Suppl 13 : S3 S10.
28. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al 2002). Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 359 : 995 1003. (Pubitemid 34286536)
29. Dalla Vestra M, Simioni N, Masiero A (2009). Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy. Int Urol Nephrol 41 : 119 126.
30. Davis JO (1959). Mechanisms regulating the secretion and metabolism of aldosterone in experimental secondary hyperaldosteronism. Recent Prog Horm Res 17 : 293 352.
31. Davis LK, Rodgers BD, Kelley KM (2008). Angiotensin II- and glucose-stimulated extracellular matrix production: mediation by the insulin-like growth factor (IGF) axis in a murine mesangial cell line. Endocrine 33 : 32 39.
32. Deschepper CF (1994). Angiotensinogen: hormonal regulation and relative importance in the generation of angiotensin II. Kidney Int 46 : 1561 1563.
33. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group (2002). Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 360 : 752 760.
34. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA et al 2008). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 19 : 2388 2442.
35. Dimmeler S, Zeiher AM (2000). Reactive oxygen species and vascular cell apoptosis in response to angiotensin II and pro-atherosclerotic factors. Regul Pept 90 : 19 25.
36. Dostal DE, Baker KM (1999). The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 85 : 643 650.
37. Doulton TW, He FJ, MacGregor GA (2005). Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45 : 880 886.
38. Düsing R, Sellers F (2009). ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr Med Res Opin 25 : 2287 2301.
39. Dzau VJ (1987). Renal and circulatory mechanisms in congestive heart failure. Kidney Int 31 : 1402.
40. Elliott HL (2009). Focus on the ONTARGET results. J Hypertens 27 : S8 S10.
41. Ennezat PV, Berlowitz M, Sonnenblick EH, Le Jemtel TH (2000). Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep 2 : 258 262.
42. Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M (1995). Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) study group. Eur Heart J 16 : 1892 1899.
43. Ezekowitz JA, McAlister FA (2009). Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 30 : 469 477.
44. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G et al 2000). Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355 : 1575 1581.
45. Fox KM, The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators (2003). Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 : 782 788.
46. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN (1984). The neurohumoral axis in congestive heart failure. Ann Intern Med 101 : 370 377.
47. Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N et al 2009). Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 4 : 361 368.
48. de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A et al 2009). Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 20 : 883 892.
49. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B et al 2001). Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 : 421 426.
50. Giacchetti G, Sechi LA, Rilli S, Carey RM (2005). The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 16 : 120 126.
51. Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL et al 2000). Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J 139 : 609 617.
52. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B et al 2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 : 772 776. (Pubitemid 37093917)
53. Gross F (1958). Renin und hypertensin, physiologische oder pathologische Wirkstoffe? Klin Wochenschr 36 : 693 706.
54. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (1994). Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343 : 1115 1122.
55. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (1996). Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. J Am Coll Cardiol 27 : 337 344.
56. Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R et al 1999). Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA group. Lancet 353 : 793 796.
57. Hackenthal E, Paul M, Ganten D, Taugner R (1990). Morphology, physiology, and molecular biology of renin secretion. Physiol Rev 70 : 1067 1116.
58. Hall JE (2003). Historical perspective of the renin-angiotensin system. Mol Biotechnol 24 : 27 39.
59. Hall AS, Murray GD, Ball SG (1997). Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute infarction ramipril efficacy. Lancet 349 : 1493 1497.
60. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B et al 1999a). Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 354 : 1751 1756.
61. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al 1999b). Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 : 611 616. (Pubitemid 29087980)
62. Heart Outcomes Prevention Evaluation Study Investigators (2000). Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 : 253 259.
63. Hebert LA, Bain RP, Verme D, Cattran D, Whittier FC, Tolchin N et al 1994). Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kidney Int 46 : 1688 1693.
64. Hedner T, Hansson L, Himmelmann A (1998). The renin-angiotensin system - a century of progress. Blood Press 7 : 68 70.
65. Hovind P, Tarnow L, Rossing P, Carstensen B, Parving HH (2004). Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. Kidney Int 66 : 1180 1186.
66. Howlett JG, McKelvie RS, Arnold JM, Costigan J, Dorian P, Ducharme A et al 2009). Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. Can J Cardiol 25 : 85 105.
67. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al 2009). 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 : e391 e479.
68. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group (1995). ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 345 : 669 685.
69. Isnard R, Pousset F, Trochu J, Chafirovskaïa O, Carayon A, Golmard J et al 2000). Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol 86 : 417 421.
70. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V et al 2008). Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359 : 2417 2428.
71. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J (2007). Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 24 : 486 493.
72. Johnston CI (1992). Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens Suppl 10 : S13 S26.
73. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al 2004). Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 : 2022 2031.
74. Kagami S, Border WA, Miller DE, Noble NA (1994). Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93 : 2431 2437.
75. Kageyama R, Ohkubo H, Nakanishi S (1984). Primary structure of human preangiotensinogen deduced from the cloned cDNA sequence. Biochemistry 23 : 3603 3609.
76. Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S et al 2008). Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med 233 : 4 11.
77. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF (1993). Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 118 : 129 138.
78. Kawano H, Do YS, Kawano Y, Starnes V, Barr M, Law RE et al 2000). Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 101 : 1130 1137.
79. Kidney Disease Outcomes Quality Initiative (K/DOQI) (2004). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 : S1 290.
80. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K et al 1995). A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study group. N Engl J Med 333 : 1670 1676.
81. Konstam MA, Neaton JD, Poole-Wilson PA, Pitt B, Segal R, Sharma D et al 2005). Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). Am Heart J 150 : 123 131.
82. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA et al 2009). Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374 : 1840 1848.
83. Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N et al 2004). Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 6 : 937 945.
84. Kum LC, Yip GW, Lee PW, Lam YY, Wu EB, Chan AK et al 2008). Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure. Int J Cardiol 125 : 16 21.
85. Latini R, Tognoni G, Maggioni AP, Baigent C, Braunwald E, Chen ZM et al 2000). Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol 35 : 1801 1807.
86. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR (2004). Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 141 : 693 704.
87. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993). The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 : 1456 1462.
88. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB (2001). Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 : 851 860.
89. Lijnen P, Petrov V (2000). Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 32 : 865 879.
90. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al 2003). The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21 : 875 886. (Pubitemid 36677151)
91. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR et al 1994). Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90 : 2056 2069.
92. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J et al 1999). Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study investigators. Circulation 100 : 1056 1064.
93. MacMahon S, Sharpe N, Gamble G, Clague A, Mhurchu CN, Clark T et al 2000). Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of atherosclerosis with ramipril. J Am Coll Cardiol 36 : 438 443.
94. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL et al 2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 : 767 771. (Pubitemid 37093916)
95. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al 2007). 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28 : 1462 1536.
96. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J et al 2008). Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372 : 547 553.
97. Matsumori A, Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-J) Study Investigators (2003). Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 5 : 669 677.
98. Ménard J, Bouhnik J, Clauser E, Richoux JP, Corvol P (1983). Biochemistry and regulation of angiotensinogen. Clin Exp Hypertens A 5 : 1005 1019.
99. Murdoch DR, McDonagh TA, Farmer R, Morton JJ, McMurray JJ, Dargie HJ (2001). ADEPT: addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J 141 : 800 807.
100. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T (2003). Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361 : 117 124. (Pubitemid 36092015)
101. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF (2009). Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 8 : CD007004.
102. Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trialists' Collaboration (2000). Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 356 : 1955 1964.
103. Ng KK, Vane JR (1967). Conversion of angiotensin I to angiotensin II. Nature 216 : 762 766.
104. Packer M (1992). The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20 : 248 254.
105. Page IH, Helmer OM (1940). A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator. J Exp Med 71 : 29 42.
106. Parving HH, Hommel E, Jensen BR, Hansen HP (2001a). Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 60 : 228 234.
107. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P et al 2001b). The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 : 870 878.
108. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L et al 2007). Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 : 829 840.
109. Paul M, Poyan Mehr A, Kreutz R (2006). Physiology of local renin-angiotensin systems. Physiol Rev 86 : 747 803.
110. Perondi R, Saino A, Tio RA, Pomidossi G, Gregorini L, Alessio P et al 1992). ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. Circulation 85 : 2004 2013.
111. Persson PB, Skalweit A, Thiele BJ (2004). Controlling the release and production of renin. Acta Physiol Scand 181 : 375 381.
112. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP et al 2003). Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 : 1893 1906.
113. Phillips MI, Kagiyama S (2002). Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs 3 : 569 577.
114. Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM (2007). Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 167 : 1930 1936.
115. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I et al 1997). Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349 : 747 752.
116. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ et al 2000). Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 : 1582 1587.
117. Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H et al 2001). QUIET Study Group. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 87 : 1058 1063.
118. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G et al 2005). Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations. J Am Soc Nephrol 16 : 3027 2037.
119. PROGRESS Collaborative Group (2001). Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 : 1033 1041.
120. Quinn SJ, Williams GH (1988). Regulation of aldosterone secretion. Annu Rev Physiol 50 : 409 426.
121. Raman VK, Lee YA, Lindpaintner K (1995). The cardiac renin-angiotensin- aldosterone system and hypertensive cardiac hypertrophy. Am J Cardiol 76 : 18D 23D.
122. Ravid M, Savin H, Jutrin I, Bental T, Lang R, Lishner M (1994). Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int Suppl 45 : S161 S164.
123. Redgrave J, Rabinowe S, Hollenberg NK, Williams GH (1985). Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives. J Clin Invest 75 : 1285 1290.
124. Remes J (1994). Neuroendocrine activation after myocardial infarction. Br Heart J 72 : S65 S69.
125. Rodrigues EJ, Eisenberg MJ, Pilote L (2003). Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med 115 : 473 479.
126. Ruiz-Ortega M, Rupérez M, Esteban V, Rodríguez-Vita J, Sánchez-López E, Carvajal G et al 2006). Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 21 : 16 20.
127. Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR et al 1994). Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE investigators. Circulation 90 : 1731 1738.
128. Sadoshima J, Izumo S (1993). Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73 : 413 423.
129. Schmidt-Ott KM, Kagiyama S, Phillips MI (2000). The multiple actions of angiotensin II in atherosclerosis. Regul Pept 93 : 65 77.
130. Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J et al 2003). The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 7 : 1699 1703.
131. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J et al 2005). Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 6 : 1218 1226.
132. Schrijvers BF, De Vriese AS, Flyvbjerg A (2004). From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25 : 971 1010.
133. Schunkert H, Ingelfinger JR, Hirsch AT, Tang SS, Litwin SE, Talsness CE et al 1992). Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 90 : 1523 1529.
134. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S et al 2005). Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54 : 3442 3452.
135. Singh R, Alavi N, Singh AK, Leehey DJ (1999). Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 48 : 2066 2073.
136. Singh R, Singh AK, Alavi N, Leehey DJ (2003). Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 14 : 873 880.
137. Skeggs LT Jr., Lentz KE, Kahn JR, Shumway NP, Woods KR (1956). The amino acid sequence of hypertensin. II. J Exp Med 104 : 193 197.
138. Skeggs LT Jr., Kahn JR, Lentz K, Shumway NP (1957a). The existence of two forms of hypertensin. J Exp Med 99 : 275 282.
139. Skeggs LT Jr., Kahn JR, Lentz K, Shumway NP (1957b). The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 106 : 439 453.
140. Skeggs LT, Dorer FE, Kahn JR, Lentz KE, Levine M (1976). The biochemistry of the renin-angiotensin system and its role in hypertension. Am J Med 60 : 737 748.
141. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H (1992). Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327 : 678 684.
142. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993). Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 : 821 828.
143. The CONSENSUS Trial Study Group (1987). Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 : 1429 1435.
144. The Microalbuminuria Captopril Study Group (1996). Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 39 : 587 593.
145. The SOLVD Investigators (1991). Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med 325 : 293 302.
146. The SOLVD Investigators (1992). Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 : 685 691.
147. Tigerstedt R, Bergman P (1898). Niere und Kreislauf. Skand Arch Physiol 8 : 223 271.
148. Topouchian J, El Feghali R, Pannier B, Wang S, Zhao F, Smetana K et al 2007). Arterial stiffness and pharmacological interventions - the TRanscend arterial stiffNess Substudy (TRANS study). Vasc Health Risk Manag 3 : 381 387.
149. Torp-Pedersen C, Kober L (1995). Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril cardiac evaluation. Lancet 354 : 9 12.
150. Vaney C, Waeber B, Turini G, Margalith D, Brunner HR, Perret C (1984). Renin and the complications of acute myocardial infarction. Chest 86 : 40 43.
151. Viberti G, Mogensen CE, Groop LC, Pauls JF (1994). Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 271 : 275 279.
152. Weber KT, Brilla CG (1991). Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83 : 1849 1865.
153. Weiss D, Sorescu D, Taylor WR (2001). Angiotensin II and atherosclerosis. Am J Cardiol 87 : 25C 32C.
154. Wilmer WA, Hebert LA, Lewis EJ, Rohde RD, Whittier F, Cattran D et al 1999). Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 34 : 308 314.
155. Wilson HM, Haites NE, Booth NA (1997). Effect of angiotensin II on plasminogen activator inhibitor-1 production by cultured human mesangial cells. Nephron 77 : 197 204.
156. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med 342 : 145 153.
157. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA et al 2008a). Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359 : 1225 1237.
158. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I et al 2008b). Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372 : 1174 1183.
159. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H et al 2008c). Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 : 1547 1559.